This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Krabbe Disease (Globoid Cell Leukodystrophy)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E75.2 | Special Copayment Reduction: V117 | Special Copayment Reduction period: 5 years
B. SynonymsGloboid cell leukodystrophy, Galactosylceramide Lipidosis, galactocerebrosidosis, galactosylceramidase deficiency
C. Adult onsetLow likelihood of first onset in adulthood — most cases manifest in infancy (within 6 months of birth), but late-onset forms manifesting in adolescence or adulthood are rarely reported.
1. HistoryFirst described by Krabbe in 1916, enzyme deficiency confirmed in 1970, GALC gene identified
2. CausesGALC gene mutations → galactocerebrosidase deficiency → accumulation of the neurotoxin psychosine
3. GeneticsAutosomal recessive, GALC (14q31.3), 30kb deletion and about 200 mutations reported
4. Epidemiology1~2 per 100,000 births, relatively high frequency in people of Northern European descent, infantile form in the majority
5. PathophysiologyDeath of myelinating cells due to accumulation of the neurotoxin psychosine → demyelination → formation of globoid cells
6. SymptomsInfantile form: irritability, spasticity and seizures followed by rapid neurological regression; late-onset form: seizures, visual loss, ataxia
7. SignsHyperreflexia followed by flaccid paralysis, white matter changes on brain MRI, nerve conduction abnormalities, elevated CSF protein
8. ScreeningNewborn screening based on DBS GALC enzyme activity performed in some US states such as New York
9. DiagnosisMeasurement of leukocyte GALC enzyme activity + GALC gene analysis, measurement of plasma psychosine concentration
10. TreatmentHSCT before symptom onset is the only effective treatment; symptomatic treatment after symptom onset
11. PrognosisInfantile form without treatment usually fatal before age 2; early HSCT can delay neurological progression
12. PreventionGenetic counseling, carrier testing, preimplantation genetic diagnosis, early intervention through newborn screening
13. ReferencesKrabbe K. A new familial, infantile form of diffuse brain sclerosis and 9 other papers

1. History

Krabbe disease was named after the Danish pediatric neurologist Knud Krabbe, who in 1916 first described two sibling cases with onset in infancy, rapidly progressive neurological regression and characteristic brain tissue findings. Krabbe observed that multinucleated giant cells characteristically form within the cerebral white matter in this disease and named them 'globoid cells,' from which the pathological name 'globoid cell leukodystrophy' derives.

For decades thereafter the metabolic cause of this disease remained unknown, until in 1970 Otto Christensen and Niels Asmussen of Austria and Lars Svennerholm of Sweden discovered that the activity of galactocerebrosidase (GALC), the enzyme that degrades galactosylceramide, was markedly reduced in patients' brains. In the 1970s, psychosine (galactosylsphingosine) was shown to be a toxic lipid that accumulates abnormally in Krabbe disease, from which the psychosine toxicity hypothesis developed.

In 1993, Sakai and colleagues first cloned and sequenced the GALC gene, after which various pathogenic mutations began to be reported. In 1995, Wenger et al. discovered the 30kb deletion mutation in the GALC gene, the most common cause of infantile Krabbe disease. In the 2000s, pathophysiological research and exploration of treatment strategies using the Twitcher mouse model were actively pursued, and the addition of Krabbe disease to newborn screening by New York State in the USA in 2006 became a major milestone in this field.

2. Causes

The root cause of Krabbe disease is functional deficiency of the lysosomal enzyme galactocerebrosidase (GALC; also called galactosylceramidase) due to pathogenic variants of the GALC gene. GALC catalyzes the hydrolysis of galactosylceramide (GalCer) and galactosylsphingosine (psychosine) within lysosomes. Galactosylceramide is abundant as a component of myelin in the central and peripheral nervous systems and is normally continuously degraded during myelin turnover.

The most important pathological consequence of GALC deficiency is accumulation of psychosine in the nervous system. Psychosine, also called galactosylsphingosine, is a lysosphingolipid that is normally maintained at very low concentrations. However, in GALC deficiency, psychosine continuously generated during myelin synthesis and degradation cannot be broken down and accumulates, exerting cytotoxicity. Psychosine destabilizes the membrane structures of various organelles including lysosomes and induces apoptosis, mitochondrial dysfunction and oxidative stress, selectively killing the myelinating cells, oligodendrocytes and Schwann cells.

3. Genetics

Krabbe disease is inherited in an autosomal recessive manner, and the causative gene, GALC, is located at chromosome 14q31.3. The GALC gene spans about 60kb and consists of 17 exons. To date, more than 200 pathogenic GALC variants have been reported, including various types such as missense, nonsense and splice-site variants and large deletions.

The most common pathogenic variant is an approximately 30kb deletion within the GALC gene (c.1489-1507del), found in about 35~40% of patients with infantile Krabbe disease. This deletion variant is particularly common in patients of Northern European and European descent. Other common variants include p.Gly270Asp (common in the infantile form) and p.Arg168Cys (associated with the late-onset form). Regarding genotype-phenotype correlations, homozygosity for variants causing severe loss of function, such as the 30kb deletion or p.Gly270Asp, results in the severe infantile phenotype, whereas missense variants with some residual enzyme activity tend to be associated with late-onset or adult forms. A correlation between plasma psychosine concentration and clinical severity has also been reported.

4. General epidemiology

The incidence of Krabbe disease is estimated at about 1~2 per 100,000 births, with some studies reporting 1.1~2.0 per 100,000. It occurs worldwide, but is reported at relatively high frequency in populations of Northern European descent (Scandinavia, UK). High-frequency clusters have also been reported in the Druze community and Muslim Arab communities in Israel.

Krabbe disease is classified into the infantile form (early infantile: onset within 6 months of birth), late infantile form (6 months~3 years), juvenile form (3~8 years) and adolescent/adult form (8 years or older). 85~90% of all patients have the infantile form, and the remaining 10~15% have late-onset forms (late infantile~adult). In the USA, some states such as New York, Kentucky, Illinois and Missouri include Krabbe disease in newborn screening, making it possible to identify patients before symptom onset. There is no difference in incidence between males and females.

5. Pathophysiology

The core pathophysiology of Krabbe disease is explained by the psychosine toxicity hypothesis. Normally, psychosine is generated as an intermediate product when galactosylceramide (GalCer), a component of myelin, is degraded, but in GALC deficiency this psychosine cannot be broken down and accumulates in the nervous system. Psychosine is particularly toxic to myelinating cells (oligodendrocytes and Schwann cells), because these cells synthesize and degrade the most myelin galactosylceramide and are therefore exposed to high concentrations of psychosine.

The identified mechanisms of psychosine cytotoxicity include ① leakage of lysosomal contents due to increased lysosomal membrane permeability, ② mitochondrial dysfunction and inhibition of oxidative phosphorylation, ③ activation of inflammatory signaling through the mitogen-activated protein kinase (MAPK) pathway, and ④ triggering of apoptotic pathways (caspase activation, release of apoptosis-inducing factors). These mechanisms act in combination to selectively kill oligodendrocytes and Schwann cells, extensively destroying myelin in the central and peripheral nervous systems. As a pathological finding, characteristic multinucleated globoid cells form within the cerebral white matter; these cells are mainly of macrophage/microglial origin and form by phagocytosing undegraded galactosylceramide.

6. Symptoms

Infantile (early infantile) Krabbe disease typically begins with symptoms between 3 and 6 months of age. Initially, nonspecific extreme irritability, photosensitivity, fever, hypertonia and feeding difficulties appear. This is followed by seizures, muscle rigidity and psychomotor developmental regression, and in the late stage, extreme rigidity (opisthotonus), quadriplegia and loss of vision and hearing appear. In its natural course, the infantile form is mostly fatal within 12~24 months of birth.

Late-onset (late infantile~adolescent/adult) Krabbe disease has a variable clinical picture. In forms with onset in childhood or adolescence, visual loss, seizures, cerebellar ataxia, cognitive decline and spastic paralysis of the limbs (spastic paraplegia) are the main symptoms. The adult form is characterized by slowly progressive spastic paraplegia of the lower limbs and peripheral neuropathy, sometimes accompanied by dementia. Due to peripheral nervous system involvement, deep tendon reflexes decrease and nerve conduction velocity is reduced. The late-onset form is clinically less severe and progresses more slowly than the infantile form, but progressive functional decline eventually follows.

7. Signs

Characteristically, the neurological examination initially shows hypertonia and hyperreflexia, which change to hypotonia and loss of deep tendon reflexes as the disease progresses. This is because demyelination of the central and peripheral nervous systems progresses simultaneously. Optic atrophy may be seen on fundus examination.

On brain MRI, T2 hyperintensity changes in the white matter of both cerebral hemispheres, the cerebellar white matter and the brainstem are characteristic, and wedge-shaped cerebellar peduncle lesions and abnormalities of the corticospinal tract are observed. In the infantile form, T1 hyperintensity of the thalamus has also been reported. Nerve conduction studies (NCS) confirm a marked decrease in motor and sensory nerve conduction velocities, reflecting peripheral nervous system demyelination. Cerebrospinal fluid (CSF) examination characteristically shows a markedly elevated protein concentration (usually 100~500 mg/dL). Abnormal findings are also observed on visual evoked potential (VEP) and auditory evoked potential (ABR) testing. Plasma psychosine concentration is markedly elevated in Krabbe disease patients, with much higher concentrations in the infantile form than in the late-onset form.

8. Screening

Newborn screening for Krabbe disease was first mandated in New York State in the USA in 2006 and subsequently adopted by some US states (Kentucky, Illinois, Missouri, New Jersey, etc.). Newborn screening measures GALC enzyme activity in dried blood spots (DBS) using a fluorescent substrate (6-hexadecanoylamino-4-methylumbelliferyl-beta-D-galactopyranoside) or a mass spectrometry-based substrate. A result is judged positive when GALC enzyme activity is reduced to less than about 10~30% of normal.

For screen-positive individuals, three-step confirmatory testing is performed: ① GALC gene variant testing, ② measurement of plasma or DBS psychosine concentration, and ③ precise enzyme activity testing (leukocytes or fibroblasts). In particular, plasma psychosine concentration is a more sensitive and specific biomarker than DBS GALC enzyme activity, and higher psychosine concentrations are associated with the severe early-onset infantile phenotype. Screening algorithms are evolving toward adding psychosine measurement as a second-tier biomarker. In Korea, Krabbe disease is not yet included in the national newborn screening panel, but the need to expand screening for lysosomal storage diseases is being discussed.

9. Diagnosis

Krabbe disease is confirmed through ① biochemical enzyme activity testing and ② molecular genetic testing. Biochemically, GALC enzyme activity is measured in peripheral blood leukocytes or cultured skin fibroblasts, and in patients it is markedly reduced to less than 5% of normal. In heterozygous carriers it is about 50% of normal. Molecular genetic confirmation is the identification of pathogenic variants in both alleles of the GALC gene.

As criteria for clinical diagnosis, ① neurological regression with onset in infancy, ② characteristic white matter changes on brain MRI, ③ elevated CSF protein, ④ abnormal nerve conduction studies and ⑤ reduced GALC enzyme activity are judged comprehensively. Measurement of plasma psychosine concentration (LC-MS/MS) can be used as a diagnostic biomarker, and an elevation of 3 times normal or more strongly suggests Krabbe disease. The differential diagnosis includes other leukodystrophies (MLD, Pelizaeus-Merzbacher disease, Canavan disease, Alexander disease), organic acidemias and mitochondrial encephalomyopathies. Prenatal diagnosis is possible by measurement of GALC enzyme activity and genetic testing in amniocytes or CVS.

10. Treatment

The currently most effective treatment for Krabbe disease is hematopoietic stem cell transplantation (HSCT), but its effect is limited to cases in which transplantation is performed before symptom onset. In infantile-form patients transplanted before symptom onset, neurological development is maintained and survival is prolonged after transplantation, whereas the benefit of transplantation is limited in patients transplanted after symptom onset. This is because HSCT cannot restore already destroyed myelin and is more effective in suppressing further damage. This concept was demonstrated in the New York State newborn screening program in the USA.

Cord blood transplantation (CBT) is the most commonly applied transplantation method in infantile Krabbe disease, and when performed before symptom onset, long-term survival is possible in about 60% or more, with neurological development reported to be maintained. As for enzyme replacement therapy (ERT), because the GALC enzyme does not cross the blood-brain barrier, ERT alone has limited effect, but strategies such as combination with HSCT or direct intracerebral administration are being studied. As gene therapy, direct CNS delivery of the GALC gene using AAV vectors has shown promising results at the preclinical stage, and entry into clinical trials is being prepared. Symptomatic treatment includes anticonvulsants, muscle relaxants, nutritional support and pain management.

11. Prognosis

In infantile Krabbe disease, most patients die within 12~24 months of birth without treatment. In infantile-form patients who received HSCT before symptom onset, maintenance of neurological development and prolonged survival have been confirmed, but long-term follow-up has reported that delays or partial deficits in cognitive and motor development remain in a considerable number. Among patients transplanted before symptom onset, the prognosis is better when the GALC genotype (homozygous 30kb deletion) and psychosine concentration are low.

Late-onset Krabbe disease has a better prognosis than the infantile form, but progressive decline in neurological function eventually follows. In the adolescent/adult form, it sometimes progresses slowly over decades. Short-term complications after transplantation include graft-versus-host disease (GVHD), infection and graft failure, and transplant-related mortality is reported at about 10~15%. Long-term follow-up studies report that about 50~60% of transplanted patients maintain independent walking ability until school age.

12. Prevention

Because Krabbe disease is an autosomal recessive genetic disease, when both parents are heterozygous carriers of a pathogenic GALC variant, an affected child may be born with a 25% probability in each pregnancy. Genetic counseling is essential for couples with a family history or who have already had an affected child. Parental carrier testing is performed by molecular genetic testing (GALC gene variant testing) or enzyme activity measurement.

Prenatal diagnosis is possible by measurement of GALC enzyme activity and GALC gene analysis in samples obtained by chorionic villus sampling (CVS, 10~12 weeks of gestation) or amniocentesis (16~18 weeks of gestation). Preimplantation genetic diagnosis (PGT) is a method of testing embryos after in vitro fertilization for pathogenic GALC variants and transferring only normal embryos. In particular, early detection before symptom onset through newborn screening is the most important preventive strategy, as early HSCT can prevent the progression of neurological regression. Expansion of newborn screening for lysosomal storage diseases including Krabbe disease is being discussed internationally, and its introduction also needs to be considered in Korea.

13. References

  1. Krabbe K. A new familial, infantile form of diffuse brain-sclerosis. Brain. 1916;39(1-2):74-114. DOI:10.1093/brain/39.1-2.74
  2. Suzuki K, Suzuki Y. Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase. Proc Natl Acad Sci USA. 1970;66(2):302-309. PMID: 5269252
  3. Sakai N, Inui K, Fujii N, et al. Krabbe disease: isolation and characterization of a full-length cDNA for human galactocerebrosidase. Biochem Biophys Res Commun. 1994;198(2):485-491. PMID: 8297346
  4. Wenger DA, Rafi MA, Luzi P. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. Hum Mutat. 1997;10(4):268-279. PMID: 9338580
  5. Duffner PK, Caggana M, Orsini JJ, et al. Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol. 2009;40(4):245-252. PMID: 19302948
  6. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005;352(20):2069-2081. PMID: 15901860
  7. Bellettato CM, Scarpa M. Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis. 2010;33(4):347-362. PMID: 20429032
  8. Svennerholm L, Vanier MT, Mansson JE. Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J Lipid Res. 1980;21(1):53-64. PMID: 7354994
  9. Orsini JJ, Kay DM, Saavedra-Matiz CA, et al. Newborn screening for Krabbe disease in New York State: the first eight years' experience. Genet Med. 2016;18(3):239-248. PMID: 26087176
  10. Aldosari M, Altuwaijri M, Husain AM. Brain-stem auditory and visual evoked potentials in children with Krabbe disease. Pediatr Neurol. 2004;31(5):325-328. PMID: 15519114